Best practices in developability assessments of therapeutic protein candidates in the biopharmaceutical industry

Developability of Biotherapeutics: Computational Approaches

Volumn , Issue , 2015, Pages 175-194

  Angell, Nicolas ^a   Ketchem, Randal R ^a   Daris, Kristine ^a   O'Neill, Jason W ^a   Gunasekaran, Kannan ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL STABILITY; CONTROLLED DRUG DELIVERY; MOLECULES; PURIFICATION; TARGETED DRUG DELIVERY;

BIOPHARMACEUTICAL INDUSTRY; COMMERCIAL DEMAND; PROCESS DEVELOPMENT; PRODUCT STABILITY; PRODUCTION PROCESS; QUALITY ATTRIBUTES; STRUCTURAL STABILITIES; THERAPEUTIC PROTEIN;

BIOACTIVITY;

EID: 84957649057     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b19023     Document Type: Chapter

References (32)

1. Yang, X., Xu, W., Dukleska, S., Benchaar, S., Mengisen, S., Antochshuk, V., Cheung, J., Mann, L., Babadjanova, Z., Rowand, J., Gunawan, R., McCampbell, A., Beaumont, M., Meininger, D., Richardson, D., and Ambrogelly, A. (2013). Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 5, 787-94.
2. Zurdo, J. (2013). Developability assessment as an early de-risking tool for biopharma¬ceutical development. Pharm Bioprocess 1, 29-50.
3. Saxena, V., Panicucci, R., Joshi, Y., and Garad, S. (2009). Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. J Pharm Sci 98, 1962-79.
4. Ulmer, K. M. (1983). Protein engineering. Science 219, 666-71.
5. Honegger, A., and Pluckthun, A. (2001). Yet another numbering scheme for immuno¬globulin variable domains: An automatic modeling and analysis tool. J Mol Biol 309, 657-70.
6. Kannan, G. (2012). Method of correlated mutational analysis to improve therapeutic antibodies. Google Patents.
7. Adhikari, S., Manthena, P. V., Sajwan, K., Kota, K. K., and Roy, R. (2010). A unified method for purification of basic proteins. Anal Biochem 400, 203-6.
8. Hong, P., Koza, S., and Bouvier, E. S. (2012). Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol 35, 2923-50.
9. Stackhouse, N., Miller, A. K., and Gadgil, H. S. (2011). A high-throughput UPLC method for the characterization of chemical modifications in monoclonal antibody molecules. J Pharm Sci 100, 5115-25.
10. Zhang, Q., Goetze, A. M., Cui, H., Wylie, J., Trimble, S., Hewig, A., and Flynn, G. C. (2014). Comprehensive tracking of host cell proteins during monoclonal antibody puri¬fications using mass spectrometry. MAbs 6, 659-70.
11. Shukla, A. A., Hubbard, B., Tressel, T., Guhan, S., and Low, D. (2007). Downstream pro¬cessing of monoclonal antibodies: Application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848, 28-39.
12. Shukla, A. A., and Thommes, J. (2010). Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28, 253-61.
13. Miesegaes, G., Lute, S., and Brorson, K. (2010). Analysis of viral clearance unit opera¬tions for monoclonal antibodies. Biotechnol Bioeng 106, 238-46.
14. Arosio, P., Rima, S., and Morbidelli, M. (2013). Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: From oligomers to larger aggregates. Pharm Res 30, 641-54.
15. Bondarenko, P. V., Second, T. P., Zabrouskov, V., Makarov, A. A., and Zhang, Z. (2009). Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer. J Am Soc Mass Spectrom 20, 1415-24.
16. Kotia, R. B., and Raghani, A. R. (2010). Analysis of monoclonal antibody product het¬erogeneity resulting from alternate cleavage sites of signal peptide. Anal Biochem 399, 190-95.
17. Diederich, P., Hansen, S. K., Oelmeier, S. A., Stolzenberger, B., and Hubbuch, J. (2011). A sub-two minutes method for monoclonal antibody-aggregate quantification using par¬allel interlaced size exclusion high performance liquid chromatography. J Chromatogr A 1218, 9010-18.
18. Rustandi, R. R., Washabaugh, M. W., and Wang, Y. (2008). Applications of CE SDS gel in development of biopharmaceutical antibody-based products. Electrophoresis 29, 3612-20.
19. Arakawa, T., and Timasheff, S. N. (1985). Theory of protein solubility. Methods Enzymol 114, 49-77.
20. Shire, S. J., Shahrokh, Z., and Liu, J. (2004). Challenges in the development of high protein concentration formulations. J Pharm Sci 93, 1390-402.
21. Goswami, S., Wang, W., Arakawa, T., and Ohtake, S. (2013). Developments and chal¬lenges for mAb-Based therapeutics. Antibodies 2, 452-500.
22. Ha, S., Wang, Y., and Rustandi, R. R. (2011). Biochemical and biophysical characteriza¬tion of humanized IgG1 produced in Pichia pastoris. MAbs 3, 453-60.
23. Qi, P., Volkin, D. B., Zhao, H., Nedved, M. L., Hughes, R., Bass, R., Yi, S. C., Panek, M. E., Wang, D., Dalmonte, P., and Bond, M. D. (2009). Characterization of the photo¬degradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J Pharm Sci 98, 3117-30.
24. Radmanovic, N., Serno, T., Joerg, S., and Germershaus, O. (2013). Understanding the freezing of biopharmaceuticals: First-principle modeling of the process and evaluation of its effect on product quality. J Pharm Sci 102, 2495-507.
25. Laursen, T., Hansen, B., and Fisker, S. (2006). Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 98, 218-21.
26. Thirumangalathu, R., Krishnan, S., Ricci, M. S., Brems, D. N., Randolph, T. W., and Carpenter, J. F. (2009). Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98, 3167-81.
27. Fesinmeyer, R. M., Hogan, S., Saluja, A., Brych, S. R., Kras, E., Narhi, L. O., Brems, D. N., and Gokarn, Y. R. (2009). Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res 26, 903-13.
28. Shieu, W., Torhan, S. A., Chan, E., Hubbard, A., Gikanga, B., Stauch, O. B., and Maa, Y. F. (2014). Filling of high-concentration monoclonal antibody formulations into pre-filled syringes: Filling parameter investigation and optimization. PDA J Pharm Sci Technol 68, 153-63.
29. Cheng, W., Joshi, S. B., Jain, N. K., He, F., Kerwin, B. A., Volkin, D. B., and Middaugh, C. R. (2013). Linking the solution viscosity of an IgG2 monoclonal antibody to its structure as a function of pH and temperature. J Pharm Sci 102, 4291-304.
30. Patapoff, T. W., and Esue, O. (2009). Polysorbate 20 prevents the precipitation of a monoclonal antibody during shear. Pharm Dev Technol 14, 659-64.
31. He, F., Becker, G. W., Litowski, J. R., Narhi, L. O., Brems, D. N., and Razinkov, V. I. (2010). High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 399, 141-43.
32. Sosic Z, et al. (2008). Application of imaging capillary IEF for characterization and quantitative analysis of recombinant protein charge heterogeneity. Electrophoresis 29(21), 4368-4376.: